Mycophenolate mofetil is a relatively new immunosuppressive drug approved for use in certain organ transplant patients to prevent organ rejection. It has not yet been proven to be effective for Myasthenia Gravis (MG). Studies to determine the safety and effectiveness of mycophenolate mofetil in MG are necessary. Researchers are actively studying this promising new therapy in certain patients with MG by conducting clinical trials. Clinical trials are the safest and quickest way to find new treatments that work.